米彦军 Apatinib (YN968D1) reverses multidrug …:米彦军阿帕替尼(yn968d1)逆转多药耐药…课件_第1页
米彦军 Apatinib (YN968D1) reverses multidrug …:米彦军阿帕替尼(yn968d1)逆转多药耐药…课件_第2页
米彦军 Apatinib (YN968D1) reverses multidrug …:米彦军阿帕替尼(yn968d1)逆转多药耐药…课件_第3页
米彦军 Apatinib (YN968D1) reverses multidrug …:米彦军阿帕替尼(yn968d1)逆转多药耐药…课件_第4页
米彦军 Apatinib (YN968D1) reverses multidrug …:米彦军阿帕替尼(yn968d1)逆转多药耐药…课件_第5页
已阅读5页,还剩15页未读 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

1、Apatinib (YN968D1) reverses multidrug resistance by inhibiting the function of multiple ATP-binding cassette transporters Yanjun Mi, Liwu FuState Key Laboratory of oncology in southern China, Cancer Center, Sun Yat-sen University, Guangzhou, 510060, ChinaEmail: FBackgroundA successful cancer chemoth

2、erapy is limited by multidrug resistance (MDR). The major inducers of MDR are the ABC transporters, such as ABCB1 (anthracyclins, vinca alkaloids, taxanes, and epipodophyllotoxins), ABCG2 (mitoxantrone, anthracyclins, topoisomerase I inhbitors, methotrexate).Combination of modulator with conventiona

3、l chemotherapeutic drugs to restore the sensitivity of MDR cells is a main strategy for overcoming MDR.Tyrosine kinase inhibitors (TKIs) belong to a new class of anticancer drugs.TKIs including lapatinib, erlotinib and sunitinib, have been shown to overcome ABC transporters-mediated MDR in cancer ce

4、lls.Apatinib (YN968D1) is an oral small-molecule TKI that targets VEGFR-2, RET, c-Kit and c-Src tyrosine kinases. It is conceivable that apatinib may inhibit functions of ABC transporters by binding to their ATP-binding sites.BackgroundCytotoxicity of apatinib alone in all experimental cell linesMor

5、e than 85% of cells were viable at concentrations of apatinib up to 3.0 M in all experimental cells.ABCB1ABCB1ABCG2Apatinib reversed MDR in vitroCompoundsIC50 SD (M) (fold-reversal)S1S1-M1-80 (ABCG2)Mitoxantrone0.194 0.027(1.00)13.651 0.922(1.00)+ 0.75 M Apatinib0.196 0.041(0.98)6.434 0.478*(2.12)+

6、1.5 M Apatinib0.185 0.058(1.05)2.070 0.621*(6.59)+ 3.0 M Apatinib0.136 0.067(1.42)1.188 0. 495*(11.5)+ 2.5 M FTC0.188 0.011(1.03)0.892 0.056*(15.3)Topotecan0.262 0.042(1.00)10.281 0.455(1.00)+ 0.75 M Apatinib0.264 0.022(0.99)4.089 0.026*(2.51)+ 1.5 M Apatinib0.247 0.017(1.05)2.037 0.083*(5.04)+ 3.0

7、M Apatinib0.196 0.055(1.33)1.188 0.055*(8.65)+ 2.5 M FTC0.254 0.016(1.02)0.745 0.068*(13.8)Cisplatin12.811 1.181(1.00)12.092 1.322(1.00)+ 3.0 M Apatinib12.280 1.990(1.04)12.143 1.452(1.00)HL60HL60/ADR(ABCC1)Doxorubicin 0.036 0.002(1.00)5.704 0.378(1.00)+ 0.75 M Apatinib 0.035 0.002(1.04)5.493 0.289(

8、1.03)+ 1.5 M Apatinib 0.037 0.002(0.97)5.528 0.515(1.02)+ 3.0 M Apatinib 0.033 0.004(1.09)5.719 0.595(1.00)Apatinib reversed MDR in vitroCompounds IC50 SD (M) (fold-reversal)HEK293/pcDNA3.1HEK293/ABCG2-R2HEK293/ABCB1 Mitoxantrone 0.0569 0.0035(1.00) 1.3460 0.3143(1.00) 0.1381 0.0274(1.00) + 3 M Apat

9、inib 0.0349 0.0097(1.63) 0.0655 0.0199*(20.55) 0.0616 0.0357*(2.24) + 3 M FTC 0.0528 0.0093(0.98) 0.0687 0.0126*(19.59)- + 3 M PSC833 0.0543 0.0069(1.04)- 0.0688 0.0459*(2.01) SN-38 0.0073 0.0003(1.00) 0.1530 0.1636(1.00)- + 3 M Apatinib 0.0045 0.0009(1.62) 0.0079 0.0021*(19.37)- + 3 M FTC 0.0050 0.

10、0003(1.46) 0.0085 0.0016*(18.00)- Vincristine 0.0437 0.0022(1.00- 0.6405 0.0349(1.00) + 3 M Apatinib 0.0335 0.0039(1.30)- 0.1792 0.0485*(3.57) + 10 M Verapamil 0.0450 0.0003(0.97)- 0.0514 0.0025*(12.46) Doxorubicin 0.0724 0.0054(1.00)- 1.0821 0.5424(1.00) + 3 M Apatinib 0.0512 0.0033(1.41)- 0.3168 0

11、.0045*(3.42) + 10 M Verapamil 0.0957 0.0142(0.77)- 0.0964 0.0153*(11.23) Cisplatin 1.8240 0.4728(1.00) 1.6521 0.3892(1.00) 1.4899 0.5321(1.00) + 3 M Apatinib 1.5256 0.3717(1.19) 1.4193 0.4820(1.16) 1.6479 0.2402(0.90) Effect of apatinib on the accumulation of doxorubicin Effect of apatinib on the ac

12、cumulation of rhodamine 123ApatinibExpression of ABCB1 and ABCG2ABCB1 and ABCG2 ATPase activityReverse ABCB1- and ABCG2-mediated MDR Intracellular accumulation of drugs in the MDR cells Effect of apatinib on the expression of ABCB1 and ABCG2Effect of apatinib on the expression of ABCB1 and ABCG2Effe

13、ct of apatinib on ABCB1 and ABCG2 ATPase activity950nmol/L10-12nmol/LEffect of apatinib on the phosphorylation of AKT and ERK1/2 ApatinibABCB1 and ABCG2 ATPase activityExpression of ABCB1 and ABCG2MDRIntracellular accumulation of drugs in the MDR cells ReverseBlockade of AKT and ERK1/2 activation AcknowledgmentsWe like to thank Professor Su

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论